Lupus & antiphospholipid syndrome
Real-world treatment patterns of immunosuppressants in Adults with systemic lupus erythematosus: A claims database analysis in the United States
Study context
- Population
- Adults with SLE in US claims data initiating azathioprine, belimumab, MTX or mycophenolate, July 2015–June 2019
- Participants
- 801 adults
- Exposure
- Initiators of azathioprine, belimumab, methotrexate or mycophenolate
- Methotrexaten = 282
- Mycophenolaten = 258
- Azathioprinen = 173
- Belimumabn = 88
- Outcome
- Persistence with index immunosuppressant therapy
- Follow-up
- 12 months
Methodological detailsclaims database analysis, logistic regression
- Claims database analysis
- Logistic regression
Main finding
As reported in the abstract
Persistent with index immunosuppressant therapy · 12-month follow-up
Persistent, overall
30%
Observational data: associations, not effects.
Further findings
| Outcome | Mycophenolate | Azathioprine | Belimumab |
|---|---|---|---|
| Discontinuation (most common non-persistent pattern) · 12-month follow-up | 58% | 47% | — not stated in the abstract |
| Switch to a different immunosuppressant · 12-month follow-up | — not stated in the abstract | — not stated in the abstract | 25% |
— not stated in the abstract
- Discontinuation (most common non-persistent pattern) — Discontinuation, overall
- 55%
- Switch to a different immunosuppressant — Switch, overall
- 17%
Discontinuation (most common non-persistent pattern) · 12-month follow-up
- Highest with mycophenolate, lowest with azathioprine
Switch to a different immunosuppressant · 12-month follow-up
- Highest with belimumab
Time to discontinuation or switch
- Average time to discontinuation over 3 months
- Average time to switch about 5 months
- Azathioprine tended to shorter and belimumab to longer times to discontinuation or switch
Predictors of non-persistence (overall sample)
- Care by rheumatologists vs primary care and higher co-morbidity (CCI) associated with non-persistence
- Race, number of SLE-related medications, census region, sex and age not significantly related to non-persistence
Original publication
Real-world treatment patterns of immunosuppressants in Adults with systemic lupus erythematosus: A claims database analysis in the United States. Lupus. Published 30 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →